ÂÜÀòÂÒÂ×

Sepideh Habibi, MD, serves as the Global Head of Pharmacovigilance and Risk Management at CRISPR Therapeutics, a role held since July 2020. Prior to this, Sepideh was the Head of Pharmacovigilance at REGENXBIO Inc. from March 2019 to July 2020 and Vice President, Global Head of Drug Safety and Pharmacovigilance at Sucampo Pharmaceuticals from November 2011 to June 2018. Expertise includes overseeing pharmacovigilance in clinical development and post-marketing settings, ensuring compliance with global regulatory authority reporting, and developing risk management strategies. Earlier experience includes serving as a Senior Medical Safety Physician/Medical Advisor at the International Partnership for Microbicides and as a Pharmacovigilance Scientist at Otsuka, focusing on adverse event signal detection. Sepideh also held roles in clinical research coordination and healthcare supervision, enhancing public awareness of health initiatives.